Ovation ScienceOVATF EV-to-EBIT is -1.70 as of Jul. 11, 2026. The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Ovation Science ranks worse than 145137.74% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ovation Science's Enterprise Value for the quarter that ended in Mar. 2026 was $1.00 Mil.
Ovation Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovation Science EV-to-EBIT Related Terms
Ovation Science EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ovation Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ovation Science's EV-to-EBIT falls into.
Ovation Science's current Enterprise Value is $0.72 Mil.
Ovation Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovation Science (OVATF) has a EV-to-EBIT of -1.70 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ovation Science and its competitors. According to the industry distribution chart, Ovation Science ranks #999999 out of 689 companies in the Drug Manufacturers industry.
Is Ovation Science's EV-to-EBIT too high?
Ovation Science's current EV-to-EBIT is -1.70. Based on the distribution chart, Ovation Science ranks #999999 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ovation Science's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #999999 out of 689 companies for EV-to-EBIT. This places Ovation Science in the lower half of its industry. The industry median EV-to-EBIT is 15.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ovation Science and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current EV-to-EBIT is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Ovation Science (OVATF) has a current EV-to-EBIT of -1.70. The stock's GF Value™ is $0.05, compared to a current price of $0.04 — trading 30% below its estimated fair value. The current EV-to-EBIT is -1.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ovation Science (OVATF), the current EV-to-EBIT is -1.70 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 